Beam Therapeutics Granted FDA Orphan Drug Designation for BEAM-302 in Alpha-1 Antitrypsin Deficiency
Beam Therapeutics has announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to BEAM-302, its investigational therapy for alpha-1 antitrypsin deficiency (AATD)—a rare and inherited condition that affects both the lungs and liver.
Understanding AATD and Its Challenges
AATD is caused by a genetic mutation that leads to deficient or malfunctioning alpha-1 antitrypsin (AAT) protein. This deficiency contributes to early-onset emphysema and liver disease due to the accumulation of misfolded proteins. Approximately 100,000 individuals in the U.S. have the PiZZ genotype (two copies of the Z allele), though only 10% are diagnosed.
Current treatments, such as intravenous AAT protein replacement, offer limited benefit and do not prevent long-term organ damage.
About BEAM-302
BEAM-302 is a next-generation genetic therapy designed to correct the PiZ mutation, the most common and severe form of AATD. Using an adenine base editor, BEAM-302 aims to convert a single A nucleotide to a G at the gene’s native locus—correcting the disease-causing mutation at its source.
Key Features of BEAM-302
One-time base editing therapy using adenine base editing technology
Liver-targeting LNP delivery system carrying a guide RNA and an mRNA encoding the base editor
Designed to:
Decrease toxic protein accumulation in liver cells
Elevate levels of functional AAT protein
Support normal anti-inflammatory responses
By addressing the genetic root of AATD, BEAM-302 may provide a durable therapeutic effect, surpassing the temporary benefits of protein replacement therapy.
Regulatory Milestones
In addition to orphan drug designation, BEAM-302 has achieved two key regulatory designations in 2025:
IND clearance: March 2025
Regenerative Medicine Advanced Therapy (RMAT) designation: May 2025
These designations support the drug’s clinical development and highlight its potential to address a significant unmet medical need.
Implications of Orphan Drug Designation
The FDA’s orphan drug designation provides several incentives for the development of therapies targeting rare diseases, including:
Tax credits for clinical trial expenses
Waiver of certain FDA fees
Seven years of market exclusivity upon approval
Looking Ahead
BEAM-302 is currently advancing through preclinical and early clinical development phases. As a precision genetic therapy, it represents a potentially transformative approach for patients with AATD—offering hope for a long-lasting and meaningful improvement in both liver and lung function.
Beam Therapeutics continues to pioneer base editing approaches across a range of severe genetic diseases, with BEAM-302 now standing as one of its most advanced and promising programs.
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!